Oncology Expert Insights

Drs Juloori and Carbone explore how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform first-line regimen selection for patients with driver-negative metastatic NSCLC.

Drs Bazhenova and Patel explain why describing a tumor as “MET positive” is no longer specific enough in non–small cell lung cancer.

Drs Sen and Sands discuss lurbinectedin's place in the small cell lung cancer treatment paradigm.

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss potential avenues for at-home administration in myeloma.

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss how on-body administration methods are affecting myeloma management.

Dr Chung discusses the development of atebimetinib in metastatic pancreatic cancer.

Dr Vogel highlights the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma.

Experts highlight the integration of subcutaneous therapies into the multiple myeloma treatment paradigm.

Drs Cooper and Choudhury discuss the evolving role of DLL3-targeting T-cell engagers in SCLC, with a focus on tarlatamab and how emerging trial data may reshape the current treatment paradigm across lines of therapy.

Tracy I. George, MD, discusses key factors for the diagnosis and management of systemic mastocytosis.

Elias Jabbour, MD, and Dennis Kim, MD, discuss recent data for olverembatininb and its place in CML management.

Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.

Dr Wong discusses the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in unresectable advanced cutaneous melanoma.

Dr Valerin discusses the role of liposomal irinotecan in pancreatic cancer management and factors influencing the decision to use this agent in practice.

Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.

Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in NSCLC, rather than sequencing them.

Dr Bekaii-Saab discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions.

Dr Orloff discusses the distinct biology of uveal melanoma and why it has historically resisted systemic treatment.

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

Dr Cortes and Dr Jabbour discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 FDA approval for patients with CML.

Joshua K. Sabari, MD, discusses the complexities of managing SCLC across both academic and community settings.

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC

Christopher Lieu, MD, discusses the evolving clinical role of ctDNA in GI oncology, including MRD-guided treatment decisions and liquid biopsy vs tissue testing in mCRC.

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.